View Financial HealthALR Technologies SG 配当と自社株買い配当金 基準チェック /06ALR Technologies SG配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.決済の安定と成長配当データの取得安定した配当: ALRT.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ALRT.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場ALR Technologies SG 配当利回り対市場ALRT.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ALRT.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Medical Equipment)2.1%アナリスト予想 (ALRT.F) (最長3年)n/a注目すべき配当: ALRT.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ALRT.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ALRT.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ALRT.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 19:05終値2026/06/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ALR Technologies SG Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Juan NobleTaglich Brothers, Inc.
お知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.
お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.
お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.